Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Rises By 84.6%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 125,000 shares, an increase of 84.6% from the February 13th total of 67,700 shares. Approximately 1.7% of the shares of the company are short sold. Based on an average daily trading volume, of 126,400 shares, the days-to-cover ratio is currently 1.0 days.

SAB Biotherapeutics Stock Down 1.2 %

Shares of NASDAQ:SABS traded down $0.02 during midday trading on Friday, reaching $1.61. 87,385 shares of the company traded hands, compared to its average volume of 60,134. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. SAB Biotherapeutics has a 12 month low of $1.45 and a 12 month high of $5.89. The firm’s fifty day moving average price is $2.45 and its two-hundred day moving average price is $2.93.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on SABS shares. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics presently has an average rating of “Buy” and an average target price of $12.40.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. HB Wealth Management LLC raised its stake in shares of SAB Biotherapeutics by 118.6% during the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after purchasing an additional 128,800 shares during the period. Kovitz Investment Group Partners LLC bought a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at $52,000. Northern Trust Corp bought a new stake in shares of SAB Biotherapeutics during the 4th quarter valued at $43,000. Geode Capital Management LLC raised its stake in shares of SAB Biotherapeutics by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after purchasing an additional 12,692 shares during the period. Finally, Diadema Partners LP bought a new stake in shares of SAB Biotherapeutics during the 4th quarter valued at $114,000. 7.82% of the stock is currently owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.